The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond
Standing at the milestone of the approval of the 100th therapeutic antibody, the early approved antibody products are primarily in the form of traditional IgG antibodies. In recent years, more and more non-traditional antibody formats have emerged, including bispecific antibodies, trispecific antibodies, antibody-conjugated drugs (ADC), and some complex antibody drugs in various formats such as antibody + cell, antibody + nucleic acid, antibody + small molecule, antibody + protein/peptide, etc. It is expected to the therapeutic antibody field will soon enter the new era of AntibodyPlusTM integration. The AntibodyPlusTM integration is a brand-new concept recently proposed by the Chinese Antibody Society. We firmly believe that the integration of antibody with some other therapeutic modalities is the trend in next 5~10 years.
In view of the new trend in this field, ACROBio is pleased to sponsor the CAS 2021 Annual Conference. The annual conference will be held online via Zoom and free for registration to the public. In the two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development.
Meet the speakers (partial):
This web search service is supported by Google Inc.